논문 및 학회자료
|
Preclinical characterization of FM101, a first-in-class A3 adenosine receptor modulator for the treatment of non-alcoholic steatohepatitis. European Association of the Study of Liver (EASL 2021)
Admin │ 2022-02-13 HIT 552 |
|---|
|
|
| 이전글 | Safety Evaluation of FM101, an A3 Adenosine Receptor Modulator, in Rat, for Deve... |
|---|---|
| 다음글 | Population pharmacokinetics of FM101 in healthy volunteers and long-term safety ... |